These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35456161)

  • 21. RETROSPECTIVE ANALYSIS OF PATIENTS WITH GRAVES ORBITOPATHY TREATED BY PULSES OF METHYLPREDNISOLONE, WITH A FOCUS ON ADVERSE EVENTS.
    Schovanek J; Cibickova L; Karhanova M; Kovarova D; Frysak Z; Karasek D
    Endocr Pract; 2018 Jul; 24(7):652-657. PubMed ID: 30048166
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preoperative clinical factors and visual outcomes following orbital decompression with dysthyroid optic neuropathy.
    Tagami M; Honda S; Azumi A
    BMC Ophthalmol; 2020 Jan; 20(1):30. PubMed ID: 31952487
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The treatment effect of maximal orbital decompression surgery and intravenous glucocorticoids pulse therapy for dysthyroid optic neuropathy].
    Li TY; Wang Y
    Zhonghua Yan Ke Za Zhi; 2022 Sep; 58(9):669-675. PubMed ID: 36069086
    [No Abstract]   [Full Text] [Related]  

  • 24. Efficacy and Safety of 6-Weekly versus 12-Weekly Intravenous Methylprednisolone in Moderate-to-Severe Active Thyroid-Associated Ophthalmopathy.
    Lai KKH; Aljufairi FMAA; Li CL; Ngai AKY; Yeung CSK; Fong RHY; Yip WWK; Young AL; Pang CP; Chong KKL
    J Clin Med; 2023 May; 12(9):. PubMed ID: 37176682
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical features of dysthyroid optic neuropathy: a European Group on Graves' Orbitopathy (EUGOGO) survey.
    McKeag D; Lane C; Lazarus JH; Baldeschi L; Boboridis K; Dickinson AJ; Hullo AI; Kahaly G; Krassas G; Marcocci C; Marinò M; Mourits MP; Nardi M; Neoh C; Orgiazzi J; Perros P; Pinchera A; Pitz S; Prummel MF; Sartini MS; Wiersinga WM;
    Br J Ophthalmol; 2007 Apr; 91(4):455-8. PubMed ID: 17035276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapy of moderate-to-severe Graves' orbitopathy with intravenous methylprednisolone pulses is not associated with loss of bone mineral density.
    Rymuza J; Popow M; Żurecka Z; Przedlacki J; Bednarczuk T; Miśkiewicz P
    Endocrine; 2019 May; 64(2):308-315. PubMed ID: 30506426
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical characteristics of dysthyroid optic neuropathy].
    Elyashiv S; Skaat A; Ben Simon G; Huna-Baron R
    Harefuah; 2015 Feb; 154(2):98-102, 137. PubMed ID: 25856861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of Rituximab After Orbital Decompression Surgery in Two Grave's Ophthalmopathy Patients Progressing to Optic Neuropathy.
    Zhang B; Li Y; Xu W; Peng B; Yuan G
    Front Endocrinol (Lausanne); 2020; 11():583565. PubMed ID: 33193097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Methylprednisolone pulse therapy for patients with dysthyroid optic neuropathy.
    Ph Mourits M; Kalmann R; Sasim IV
    Orbit; 2001 Dec; 20(4):275-280. PubMed ID: 12045904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Decrease in Bone Formation and Bone Resorption during Intravenous Methylprednisolone Pulse Therapy in Patients with Graves' Orbitopathy.
    Rymuza J; Gutowska K; Kurpios-Piec D; Struga M; Miśkiewicz P
    J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36078937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves' ophthalmopathy.
    Le Moli R; Baldeschi L; Saeed P; Regensburg N; Mourits MP; Wiersinga WM
    Thyroid; 2007 Apr; 17(4):357-62. PubMed ID: 17465867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic factors for significant 6-month recovery in dysthyroid optic neuropathy in a tertiary center: A series of 69 eyes in 38 patients.
    Vermot-Desroches V; Thia-Soui-Tchong K; Raymond P; Filip A; Orgiazzi J; Jouanneau E; Froment Tilikete C; Borson-Chazot F; Manet R; Abeillon Du Payrat J
    Ann Endocrinol (Paris); 2023 Aug; 84(4):430-439. PubMed ID: 37086950
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional outcomes and complications in refractory dysthyroid optic neuropathy management: Experience with 3 different surgical protocols.
    Dallan I; Cristofani-Mencacci L; Fiacchini G; Benettini G; Picariello M; Lanzolla G; Lazzerini F; Rocchi R; Turri-Zanoni M; Menconi F; Sellari-Franceschini S; Marinò M
    Am J Otolaryngol; 2022; 43(3):103451. PubMed ID: 35439657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment with Intravenous Methylprednisolone in Patients with Graves' Orbitopathy Significantly Affects Adrenal Function: Assessment of Serum, Salivary Cortisol and Serum Dehydroepiandrosterone Sulfate.
    Pelewicz K; Szewczyk S; Miśkiewicz P
    J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33050327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sight-Threatening Graves' Ophthalmopathy during the Third Trimester of Pregnancy: A Case Report.
    Sakurai K; Inoue T; Niitsuma S; Sato R; Takahashi K; Arihara Z
    Tohoku J Exp Med; 2020 Dec; 252(4):321-327. PubMed ID: 33268601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Therapeutic Effect of Combination of Orbital Decompression Surgery and Methylprednisolone Pulse Therapy on Patients with Bilateral Dysthyroid Optic Neuropathy.
    Xu J; Ye H; Chen G; Chen J; Chen R; Yang H
    J Ophthalmol; 2020; 2020():9323450. PubMed ID: 32148948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proptosis reduction by clinical vs radiological modalities and medial vs inferomedial approaches: comparison following endoscopic transnasal orbital decompression in patients with dysthyroid orbitopathy.
    Thapa S; Gupta AK; Gupta A; Gupta V; Dutta P; Virk RS
    JAMA Otolaryngol Head Neck Surg; 2015 Apr; 141(4):329-34. PubMed ID: 25654307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optical coherence tomography measurements in compressive optic neuropathy associated with dysthyroid orbitopathy.
    Park KA; Kim YD; In Woo K; Kee C; Han JC
    Graefes Arch Clin Exp Ophthalmol; 2016 Aug; 254(8):1617-1624. PubMed ID: 27169807
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Augmented endoscopic orbital apex decompression in dysthyroid optic neuropathy.
    Singh S; Curragh DS; Selva D
    Eye (Lond); 2019 Oct; 33(10):1613-1618. PubMed ID: 31068660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of rituximab in treating steroid-resistant Graves' orbitopathy in active moderate-to-severe and sight-threatening forms: A retrospective observation from China.
    Zhang Z; Feng X; Guo Y; Kang X; Wang D; Zhang J; Zeng Z; Yuan G
    Heliyon; 2024 Jun; 10(11):e31932. PubMed ID: 38867959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.